Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer

NCT03206203 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT03206203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03206203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
August 29, 2017
Completion date
October 4, 2023
Enrollment
106 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

her2 negative, invasive breast cancer, stage iv breast cancer, triple negative breast cancer